[Effect of high-titer plasma in pediatric patients with severe adenovirus pneumonia].

To explore the efficacy and safety of high-titer plasma in the treatment of pediatric patients with severe adenovirus pneumonia. The clinical data of 92 pediatric patients with severe adenovirus pneumonia admitted to pediatric intensive care unit (PICU) in Guangzhou Women and Children's Medical Center from January 2016 to October 2019 were retrospectively collected. According to the treatment with or without high-titer plasma, the patients were divided into plasma treatment group (41) and non-plasma treatment group (51). The 51 patients with chest radiograph showing more than half the lungs involved were divided into plasma treatment group (29) and non-plasma treatment group (22). According to fever duration before plasma treatment, patients were divided into early group (≤5 days, 5), middle group (>5-10 days, 14), and late group (>10 days, 22). Baseline data, therapeutic effects, and prognosis of patients in each group were analyzed with test, non-parametric rank sum test, one-way ANOVA and chi-square test. Ninety-two patients were included. There were no significant differences in age, gender, body weight, fever duration, sequential organ failure assessment, and Murray lung injury score between plasma treatment group and non-plasma treatment group before admission (all 0.05). The proportion of patients whose temperature drop to normal within 5 days was higher in plasma treatment group than that in non-plasma treatment group (88% (36/41) 69% (35/51), χ(2)=4.745, 0.029). However, there were no significant differences between the two groups in the proportions of invasive ventilator weaning within 14 days (63% (26/41) . 76% (39/51), χ(2)=1.868, 0.172), transfer out from PICU within 14 days (49% (20/41) . 69% (35/51), χ(2)=3.724, 0.054), discharge within 28 days (51% (21/41) . 61%(31/51), χ(2)=0.846, 0.358) and survived patients (85% (35/41) . 76%(39/51), χ(2)=1.143, 0.285). Among patients with severe chest radiograph, the proportions of patients whose temperature drop to normal within 5 days and survived patients were higher in plasma treatment group than those in non-plasma treatment group (86% (25/29) . 59% (13/22), χ(2)=4.843, 0.028; 83% (24/29) . 55%(12/22), χ(2)=4.796, 0.029, respectively). However, there were no significant differences between the two groups in the proportions of invasive ventilator weaning within 14 days (52% (15/29) . 59% (13/22), χ(2)=0.274, 0.601), transfer out from PICU within 14 days (34% (10/29) . 45% (10/22), χ(2)=0.632, 0.427), and discharge within 28 days (45% (13/29) . 45% (10/22), χ(2)=0.002, 0.964). Among early, middle and late group, the proportions of invasive ventilator weaning within 14 days were 2/5, 13/14 and 50% (11/22), respectively, with statistically significant difference (χ(2)=8.119, 0.017). There were no significant differences in the proportions of patients whose temperature drop to normal within 5 days (4/5, 14/14, 82% (18/22), χ(2)=2.965, 0.227), transfer out from PICU within 14 days (2/5, 10/14, 36%(8/22), χ(2)=4.386, 0.112), discharge within 28 days (2/5, 8/14, 50% (11/22), χ(2)=0.462, 0.794) and survived patients (4/5, 13/14, 82% (18/22), χ(2)=0.966, 0.617) in the three groups. Only one case with high-titer plasma therapy had rash in the course of infusing plasma and no other adverse reactions were observed. High-titer plasma can shorten the fever time and improve the proportion of survival patients in pediatric severe adenovirus pneumonia. The clinical effect of high-titer plasma is better in 5-10 days of fever course. High-titer plasma is an effective and safe treatment.